PALB2 and metastatic prostate carcinoma: The SU2C cohort is comprised of metastatic prostate cancer cases and 3 of 429 (0.7%) cases had a presumed deleterious PALB2 alteration while 5 of 429 (1.2%) cases had a predicted deleterious BARD1 alteration (Fig. 1b)5.